P3 Health Partners Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PIII research report →
Range $23 – $23
Price Chart
About the company
P3 Health Partners Inc. , a patient-centered and physician-led population health management company, provides superior care services in the United States. The company operates clinics and wellness centers.
- CEO
- Aric Coffman
- IPO
- 2021
- Employees
- 320
- HQ
- Henderson, NV, US
Get TickerSpark's AI analysis on PIII
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.54M
- P/E
- -0.08
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.06
- EV/EBITDA
- 38.19
- Div Yield
- 0.00%
- Gross Margin
- 57.69%
- Op Margin
- -5.24%
- Net Margin
- -3.30%
- ROE
- 171.75%
- ROIC
- -23.42%
Latest fiscal year · YoY change
- Revenue
- $1.46B-2.8%
- Gross Profit
- $-144,323,000-109.6%
- Op Income
- $-270,301,000
- Net Income
- $-147,948,000-8.9%
- EPS
- $-45.26+3.3%
- OCF Growth
- +17.2%
- FCF Growth
- +17.2%
- 52W High
- $16.89
- 52W Low
- $1.52
- 50D MA
- $4.87
- 200D MA
- $6.59
- Beta
- 1.80
- RSI (14)
- 21
- Avg Volume
- 30.85K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
P3 Health Partners posted a strong third quarter, with reported Adjusted EBITDA up sharply and full-year guidance raised on improved medical cost management, utilization, and payer economics.· November 9, 2026
- Q3 Adjusted EBITDA was $21 million, and full-year 2026 guidance was raised to $90 million-$110 million, with the midpoint increased to $100 million.
- Revenue was approximately $396 million, up 15% from $345 million a year ago; medical claims expense was approximately $322 million and medical margin was about $44 million.
- Underlying Q3 Adjusted EBITDA was approximately $10 million after about $7 million of favorable medical margin from CMS ACO reconciliation and about $5 million of non-cash income.
- Management said year-to-date Medicare Advantage medical expense is 0.7% below the full-year 2025 level on a normalized basis, though Q3 trend worsened versus the first half.
- The company highlighted a more concentrated membership base, about 105,000 at-risk members and about 133,000 total lives under management including 28,000 management-services lives.
Third-quarter 2026 revenue was approximately $396 million, versus $345 million in the prior-year quarter, a 15% increase. Adjusted EBITDA was $21 million, compared with an Adjusted EBITDA loss of approximately $46 million in Q3 2025; year-to-date Adjusted EBITDA was $101 million, versus an Adjusted EBITDA loss of approximately $85 million in the same period last year. Medical claims expense was approximately $322 million; medical margin was approximately $44 million, or $140 per member per month; and the medical loss ratio was approximately 90.6% after adjusting for favorable prior period items. The company ended the quarter with approximately $44 million of cash and cash equivalents. For 2026, management raised full-year Adjusted EBITDA guidance to $90 million-$110 million, up from $80 million-$110 million previously, with the midpoint moving to $100 million from $95 million.
Aric Coffman framed the quarter as evidence that P3’s operating changes are compounding, saying the company is building a durable foundation around medical cost management, quality, disciplined growth, and operational refinement. He emphasized that utilization management, quality, and clinical programs are showing measurable improvement, and he positioned Nebraska as a template for capital-light expansion into new markets. His tone was confident and forward-looking, while also stressing that the company will pursue growth at a pace its infrastructure can support.
Leif Pedersen said Q3 marked the company’s third consecutive profitable quarter and broke out the main drivers: about $7 million of favorable medical margin from the 2025 CMS ACO reconciliation and about $5 million of non-cash income from a liability release tied to the ACO joint venture. He noted underlying Q3 Adjusted EBITDA was about $10 million and that underlying year-to-date Adjusted EBITDA was about $29 million, despite higher medical expense in the quarter. He also highlighted adjusted operating expense of approximately $35 million, cash and cash equivalents of approximately $44 million, and said the revised 2026 outlook reflects both reported year-to-date performance and current expectations for the fourth quarter.
Analysts asked about the building blocks for 2027, the size and mix of the $200 million of identified value creation, and whether membership growth next year would come through care-management arrangements or full-risk contracts. Management said it will provide more clarity after open enrollment and into early 2027, but said the $200 million is expected to be realized over multiple years and is concentrated mainly in clinical execution, then provider economics, and lastly operating efficiency. Questions also focused on the Q3 cost-trend step-up; management said the pressure was mainly on the Part B side, with some of the increase more pronounced in Nevada and tied to outpatient and professional services.
The company said its core operating levers are working: utilization management and quality had their strongest quarters of the year, and year-to-date Medicare Advantage medical expense remains 0.7% below the full-year 2025 normalized level. Management also pointed to a large identified opportunity set of more than $200 million across existing business lines, plus a repeatable model for new market entry that it believes can stay capital-light. The raised EBITDA guidance and third consecutive profitable quarter suggest the business is exiting 2026 with improved earnings power.
Management acknowledged Q3 medical expense stepped up versus the first half, driven mainly by outpatient and professional services, with some of the pressure more pronounced in Nevada. The company also said much of the $200 million opportunity will take multiple years to realize and depends on execution, which introduces timing risk. Membership was lower year over year at about 105,000 at-risk members versus about 116,000, reflecting deliberate exits from arrangements that did not meet economic thresholds.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 55.4%
- Shares Outstanding
- 3.28M
- Float Shares
- 1.82M
of shares held by institutions
19 13F filers
Buy/sell ratio 0.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eversept Partners, LP | 50.00K | ▲ 50.00K |
| Vanguard Group Inc | 48.12K | ▼ 599 |
| Vanguard Capital Management LLC | 41.33K | ▼ 152 |
| Jane Street Group, LLC | 36.53K | ▼ 17.96K |
| Citadel Advisors LLC | 23.99K | ▲ 23.99K |
| Diversified Trust Co | 23.29K | ▲ 9.85K |
| Corient Private Wealth LP | 19.74K | 0 |
| Geode Capital Management, LLC | 17.50K | ▲ 405 |
| Renaissance Technologies LLC | 12.55K | ▼ 2.60K |
| Morgan Stanley | 10.61K | ▲ 7.79K |
| Hrt Financial LP | 10.11K | ▼ 44.60K |
| Blackrock, Inc. | 7.64K | 0 |
Held by 21 ETFs
Biggest fund positions in PIII by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 13, 26 | Hudson Vegas Investment SPV, LLC | other | 100,000 |
| Aug 13, 26 | Hudson Vegas Investment SPV, LLC | other | 100,000 |
| Aug 13, 26 | Hudson Vegas Investment SPV, LLC | other | 100,000 |
| Aug 10, 26 | Hudson Vegas Investment SPV, LLC | sell | 1,041 |
| Aug 10, 26 | Hudson Vegas Investment SPV, LLC | sell | 19,074 |
| Aug 10, 26 | Hudson Vegas Investment SPV, LLC | sell | 29,885 |
| Jun 10, 26 | Hudson Vegas Investment SPV, LLC | other | 50,000 |
| Jun 10, 26 | Hudson Vegas Investment SPV, LLC | other | 50,000 |
| Jun 10, 26 | Hudson Vegas Investment SPV, LLC | other | 50,000 |
| May 8, 26 | Pedersen Leif Elliott | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PIII coverage
Recent articles, reports, and earnings notes.
No research on PIII yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PIII report →P3 Health Partners Inc. (PIII) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
P3 Health Partners Announces Third Quarter 2026 Results
businesswire.com · Nov 9
Head-To-Head Contrast: Tempus AI (NASDAQ:TEM) versus P3 Health Partners (NASDAQ:PIII)
defenseworld.net · Nov 2
P3 Health Partners Schedules Third Quarter 2026 Earnings Release and Conference Call
businesswire.com · Oct 22
20/20 Biolabs (NASDAQ:AIDX) and P3 Health Partners (NASDAQ:PIII) Head-To-Head Review
defenseworld.net · Oct 18
P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer
gurufocus.com · Oct 12
P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer
businesswire.com · Oct 12
Contrasting P3 Health Partners (NASDAQ:PIII) & McKesson (NYSE:MCK)
defenseworld.net · Sep 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.